1 pending office actions • 0 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Gbs Global Biopharma Inc. currently has 1 pending office action in its patent portfolio. This matter is being handled by 1 distinct examiner. The data indicates that there are 0 distinct art units associated with this portfolio at this time. For a practitioner, this concentration means that the portfolio's immediate progress depends on a single examiner's review of the active matter.
The busiest examiner for this portfolio is VALENROD, YEVGENY, who is responsible for 1 pending office action. This count represents the full extent of the company's current pending workload at the patent office. The presence of 0 distinct art units may reflect an application in a transitional state or a specific administrative categorization. Practitioners should evaluate the specific tendencies of this examiner to effectively manage the pending application and anticipate future office actions.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| VALENROD, YEVGENY | 1 | 72.5% | +25.1% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18663034 | CANNABINOID-CONTAINING COMPLEX MIXTURES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | VALENROD, YEVGENY | — |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18663034 | CANNABINOID-CONTAINING COMPLEX MIXTURES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | VALENROD, YEVGENY | — | §103Other | Non-Final OA | — | Pending | May 13, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialGbs Global Biopharma Inc. has 1 pending office actions as of October 2026, spread across 0 art units and 1 examiners.
Yevgeny Valenrod has the most, with 1 of Gbs Global Biopharma Inc.'s pending office actions.
